Rituximab to prevent PTLD in organ transplant patients with EBV
Treatments studied
Part of Infections clinical trials.
This trial tests whether a drug called rituximab can prevent a type of cancer called PTLD in people who have had an organ transplant and are showing signs of an EBV infection. EBV is a common virus that can be more dangerous for transplant patients, and this study aims to see if using rituximab early can stop PTLD from developing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a solid organ transplant (like kidney, liver, heart, or lung).
- You are 18 years or older.
- You have an EBV infection with a viral load of at least 1000 IU/mL on two blood tests taken at least one week apart.
- Your anti-rejection medication has been reduced, or there is a medical reason it cannot be safely reduced.
- You do not have or have not had post-transplant lymphoproliferative disorder (PTLD).
- Your life expectancy is more than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving rituximab early after a stem cell transplant can prevent a common viral infection (EBV) from becoming serious. It may help reduce complications and improve recovery.
This trial tests whether one dose of rituximab (given around the time of transplant) can help prevent a first Epstein-Barr virus (EBV) infection and related abnormal lymph node or immune growths after kidney transplant. It is specifically for adults who are EBV-negative before receiving an EBV-positive donor kidney.
This study tests a combination of two medications, loncastuximab tesirine and rituximab, as the first treatment for a type of lymphoma that can develop after an organ transplant. The goal is to see if this combination is safe and effective at shrinking or eliminating the cancer.
This trial studies tafasitamab plus rituximab to treat a type of lymphoma called post-transplant lymphoproliferative disorder (PTLD) in adults after a solid organ transplant. It’s aimed at helping stop the PTLD when it can be measured and before you’ve had PTLD treatment beyond limited measures like steroid or reducing anti-rejection drugs.
This trial tests whether adding a drug called rituximab to the standard transplant plan can help prevent Epstein-Barr virus (EBV) from reactivating in children receiving a half-matched stem cell transplant. It may help reduce a common viral complication after transplant.
This study tests a drug called epcoritamab for people who have a type of lymphoma that developed after an organ transplant and has not responded to standard treatment. The drug aims to help your immune system fight the cancer cells.
Hear when a new Epstein-Barr Virus (EBV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.